Drugs › Gonadotropin releasing hormone receptor antagonist
Generic name
Ganirelix acetate: adverse event reports filed with FDA
1,118 reports list it as a suspect or interacting product, 2005–2026. Class: Gonadotropin releasing hormone receptor antagonist. Also reported as Ganirelix Acetate Injection.
- 1,118
- reports as suspect product
- 0% of all reports · about 54 a year
- 30
- reports, 12 months to June 2026
- 65 in the 12 months before
- 32.4%
- marked serious by the reporter
- 23.4% across the class
- 0.4%
- record death among outcomes, as reported
- 5 reports · not verified by FDA
1,118 adverse event reports received by FDA list ganirelix acetate, a generic name as a suspect or interacting product, from October 2005 to June 2026. A further 377 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 30 reports listed it, down 54% from 65 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 54 reports a year and 0% of the 20,646,523 reports in the database, and 4% of the reports for the gonadotropin releasing hormone receptor antagonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded ovarian hyperstimulation syndrome (19.8%), no adverse event (8.9%) and needle issue (6.9%). A report can list several reactions, so shares add to more than 100%; 200 different terms appear across these reports. Ovarian hyperstimulation syndrome is recorded in 19.8% of these reports, with no counterpart in the median gonadotropin releasing hormone receptor antagonist drug (0%).
32.4% of the reports are marked serious by the reporter (23.4% across the class); 0.4% record death among the outcomes and 23% record hospitalisation, as reported. 38.6% of the reports came from physicians, and the largest patient age group is 18 to 44 (49.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Ganirelix acetate reports recording the termmedian drug in gonadotropin releasing hormone receptor antagonist
- Ovarian hyperstimulation syndrome19.8%221
- No adverse eventno adverse event was reported8.9%99
- Needle issuea problem with the needle6.9%77
- Product quality issuea problem with the product itself5.8%65
- Injection site painpain where the injection was given5.6%63
- Headachehead pain4.4%49
- Ascitesfluid in the abdomen3.8%43
- Drug ineffectivethe medicine did not work as expected3.7%41
- Abdominal distensiona bloated abdomen3.3%37
- Nauseafeeling sick3.3%37
- Injection site erythemaredness where the injection was given3%34
- Abdominal painstomach or belly pain2.6%29
- Dyspnoeashortness of breath2.5%28
- Poor quality device used2.5%28
- Pruritusitching2.2%25
- Product storage errorthe product was stored wrongly2.1%23
- Injection site pruritusitching where the injection was given2%22
- Maternal exposure during pregnancythe mother took the medicine during pregnancy1.9%21
- Drug dose omissiona dose was missed1.7%19
- Rashskin rash1.6%18
- Painpain, site not specified1.5%17
- Vomitingbeing sick1.4%16
- Fatiguetiredness1.3%15
- Injection site reactiona reaction where the injection was given1.3%15
- Pleural effusionfluid around the lung1.3%15
- Abortion1.3%14
- Circumstance or information capable of leading to medication errora situation that could lead to a medication error1.3%14
- Injection site urticaria1.3%14
- Incorrect product storagethe product was stored wrongly1.2%13
Top 30 of 200 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 4 drugs in the gonadotropin releasing hormone receptor antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 28,126 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 74.1% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Infertility female | 272 | 24.3% |
| In vitro fertilisation | 123 | 11% |
| Assisted reproductive technology | 113 | 10.1% |
| Infertility | 93 | 8.3% |
| Prevention of premature ovulation | 51 | 4.6% |
| Assisted fertilisation | 33 | 3% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,118 reports.
In context
| Measure | Ganirelix acetate | Gonadotropin releasing hormone receptor antagonist | All reports |
|---|---|---|---|
| Reports as suspect product | 1,118 | 28,126 | 20,646,523 |
| Share of that pool | — | 4% | 0% |
| Reports, latest 12 months | 30 | — | 1,332,454 |
| Marked serious | 32.4% | 23.4% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 4 | 38 | 91 |
| Hospitalisation recorded, per 1,000 reports | 230 | 80 | 213 |
| Consumer-filed share | 35.8% | 86.1% | 45.8% |
| Top term, share of reports | Ovarian hyperstimulation syndrome 19.8% | median 0% | 0% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the gonadotropin releasing hormone receptor antagonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Orgovyx | brand | 22,329 | 5,602 | 22.5% |
| Orilissa | brand | 3,198 | 29 | 32.4% |
| Myfembree | brand | 1,481 | 118 | 10.5% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Ganirelix acetate reports
How many adverse event reports has FDA received for Ganirelix acetate?
1,118 reports list Ganirelix acetate as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 30 of them arrived in the latest 12 months. Another 377 list it only as a concomitant medication.
What reactions are recorded in Ganirelix acetate reports?
ovarian hyperstimulation syndrome (19.8%), no adverse event (8.9%), needle issue (6.9%), product quality issue (5.8%) and injection site pain (5.6%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Ganirelix acetate was responsible.
How serious are the reports?
32.4% are marked serious by the reporter. Among the outcomes recorded, 0.4% of reports include death and 23% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (38.6%), consumer or non-health professional (35.8%) and other health professional (15.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Ganirelix acetate rising?
30 reports in the 12 months to June 2026, down 54% from 65 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Ganirelix acetate was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Ganirelix acetate?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Ganirelix acetate as a suspect or interacting product; reports listing it only as a concomitant medication (377) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.